SC
HRMY icon

Schubert & Co’s Harmony Biosciences HRMY Stock Holding History

Schubert & Co’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-15
Closed -$490 – 706
2023
Q1 		$490 Sell
15
-10
-40% -$455 ﹤0.01% 1420
2022
Q4 		$1.38K Buy
25
+9
+56% +$495 ﹤0.01% 1057
2022
Q3 		$1K Buy
16
+1
+7% +$49 ﹤0.01% 1120
2022
Q2 		$1K Buy
15
+11
+275% +$495 ﹤0.01% 1129
2022
Q1 		$0 Buy
4
+3
+300% +$122 ﹤0.01% 1187
2021
Q4 		$0 Buy
+1
New +$40 ﹤0.01% 1129

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Schubert & Co's HRMY Position: Q2 2023 in Review

Schubert & Co sold out of Harmony Biosciences (HRMY) in Q2 2023, closing a stake of 15 shares — an estimated $490 sold.

Schubert & Co first reported a position in HRMY in Q4 2021 and held it in 6 quarters. The position peaked at $1.38K in Q4 2022. 211 funds tracked by Wall St. Rank hold HRMY as of Q2 2023.

  • Schubert & Co reported no remaining Harmony Biosciences position as of Q2 2023 after selling out during the quarter.
  • Schubert & Co sold 15 Harmony Biosciences shares in Q2 2023, an estimated $490.
  • Schubert & Co first reported a position in Harmony Biosciences in Q4 2021 and held it in 6 quarters.
  • Schubert & Co's Harmony Biosciences position peaked at $1.38K in Q4 2022.
  • 211 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2023.

Based on Schubert & Co's 13F filing for Q2 2023, filed 4 Aug 2023.